Specialty Pharma Journal Specialty, Precision & Technology
TOKYO, BASKING RIDGE, N.J. and MUNICH, Jan. 18, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in a subgroup of patients with HER2-expressing gastric cancer previously treated with trastuzumab …
Tag Archives: asco
January, 2018
June, 2017
-
8 June
ASCO and Foundation Medicine Collaborate to Identify Participants for the Targeted Agent & Profiling Utilization Study
ALEXANDRIA, Va. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–The American Society of Clinical Oncology, Inc. (ASCO) and Foundation Medicine (NASDAQ: FMI) today announced entry into an agreement to create efficiencies for research sites participating in ASCO’s TAPUR™ Study in identifying potential participants for the study. ASCO is announcing that reports from Foundation Medicine’s …
-
7 June
NantKwest Announces NANT Cancer Vaccine Program Expansion Addressing Multiple Cancer Types
CULVER CITY, Calif.–(BUSINESS WIRE)–NantKwest and Nantworks today announced at the 2017 Annual American Society for Clinical Oncology meeting (ASCO) in Chicago, IL the expansion of the company’s existing NANT Cancer Vaccine program in pancreatic cancer (ClinicalTrials.gov NCT03136406) to target a number of additional tumor types. The NANT Cancer Vaccine program …
-
7 June
AstraZeneca Presents Tagrisso Data in EGFR T790M-Mutation Positive NSCLC & CNS Metastases
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today reported further evidence that Tagrisso® (osimertinib), the potential new standard of care for patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), also shows clinical activity in those patients with disease progression to central nervous system (CNS) metastases. The data, …
-
5 June
Incyte’s Epacadostat in Combination with Merck’s Keytruda Demonstrates Clinical Activity Across Multiple Tumors Types
WILMINGTON, Del. & KENILWORTH, N.J.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, will be highlighted …
-
5 June
Juno Therapeutics Presents Updated Results for its CAR-T Candidate in Aggressive NHL
SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated data from the TRANSCEND trial of JCAR017 in relapsed and refractory (r/r) aggressive B cell non-Hodgkin lymphoma (NHL) in a presentation at the 2017 Annual Meeting of the American …
-
5 June
ASCO 2017: Ovarian Cancer Drug Delivers ‘Very Promising’ Results in Early Trial
A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumors in half of women with the disease. Researchers believe the drug, which mimics the action of folic acid to enter cells, could hold huge promise for women with advanced ovarian …
May, 2017
-
26 May
President’s Budget Threatens to Stall Nation’s Progress Against Cancer
ASCO strongly opposes the Administration’s proposed cuts to federal agencies that support biomedical research and Medicaid for Fiscal Year 2018, including a 21 percent proposed funding cut for the National Institutes of Health (NIH), a 20 percent proposed funding cut for the National Cancer Institute (NCI), and reducing Medicaid funding …
-
19 May
Targeted Therapy Can Delay Recurrence of Intermediate-Stage Lung Cancer
ASCO Perspective “This study identifies a subset of patients with lung cancer who can benefit from a targeted treatment that causes far fewer side effects than chemotherapy,” said ASCO President-Elect Bruce E. Johnson, MD, FASCO. “It’s also clear evidence that we can use precision medicine not only in patients with …
-
12 May
Roche to Present New Data on Personalized Medicines and Cancer Immunotherapies at the ASCO Annual Meeting
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 2 June to 6 June in Chicago, United States. More than 190 abstracts have been accepted, including two “late breakers” …